AGIO Agios Pharmaceuticals Inc.

52.78
+2.63  (+5%)
Previous Close 50.15
Open 49.84
Price To Book 5.81
Market Cap 3,635,981,476
Shares 68,889,380
Volume 519,793
Short Ratio
Av. Daily Volume 761,502
Stock charts supplied by TradingView

NewsSee all news

  1. Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

    – TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma – CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc.

  2. Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

    – Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation – – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET – CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Agios

  3. Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

    CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that vorasidenib and

  4. Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

    CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is

  5. Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response

    – First Quarter TIBSOVO® Net Revenue of $22.7 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – New Clinical Data from Mitapivat in Thalassemia Accepted for Presentation at

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 updated data due at EHA June 11 - 14, 2020.
AG-348 - Mitapivat (EHA)
Thalassemia
FDA Approval announced July 20, 2018.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 3 data due between the end of 2020 and mid-2021.
AG-348 (ACTIVATE-T)
Pyruvate kinase deficiency
Phase 3 enrolment to be completed 2021.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
sNDA filing due to be filed following final overall survival analysis between the end of 2020 and mid-2021. Mature data due mid-2020, but anticipates delays in collecting the data due to COVID-19.
AG-120 Ivosidenib (ClarIDHy)
IDH1 mutant positive cholangiocarcinoma - cancer
Phase 1 data at ASCO June 2018 noted CR rate was 24%.
AG-120 Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
Phase 1 enrolment has slowed due to COVID-19. A go/no-go decision is expected no later than 2022.
AG-270
Solid tumors
Phase 3 enrolment has slowed as a result of COVID-19.
Vorasidenib (AG-881)
Glioma
FDA Approval announced May 2, 2019.
Ivosidenib
Frontline AML with IDH1 mutation
Phase 1 presentation at ASCO May 29, 2020.
Vorasidenib (AG-881) (ASCO)
IDHm low-grade glioma
Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib
IDH1 mutant newly diagnosed AML ineligible for standard therapies
Phase 1 updated data at ASH December 9, 2019 noted complete response (CR) rate of 61% and a CR + CR with partial hematologic recovery (CRh) rate of 70%.
Ivosidenib and azacitidine ( Vidaza)
Newly diagnosed AML with an IDH1 mutation
Phase 3 data due between the end of 2020 and mid-2021.
AG-348 - Mitapivat (ACTIVATE)
Pyruvate Kinase Deficiency
Phase 2 data due at ASH December 2020.
AG-348 - Mitapivat (ASH)
Sickle cell disease.
Phase 1 trial to commence mid-2020.
AG-946
Healthy volunteers

Latest News

  1. Agios Announces Publication of TIBSOVO® Phase 3 Data in The Lancet Oncology Demonstrating Significant Improvement in Progression-Free Survival Compared to Placebo in Previously Treated IDH1-Mutant Cholangiocarcinoma Patients

    – TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma – CAMBRIDGE, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc.

  2. Agios to Present Updated Clinical Proof-of-Concept Data from the Phase 2 Study of Mitapivat in Thalassemia in Oral Presentation at the European Hematology Association Annual Congress

    – Data Supporting Utility of TIBSOVO® in AML and MDS Also Accepted for Presentation – – Agios to Host Investor Webcast on June 12 at 7:30 a.m. ET – CAMBRIDGE, Mass., May 14, 2020 (GLOBE NEWSWIRE) -- Agios

  3. Agios to Present Updated Data from the Phase 1 Study of Vorasidenib in Non-enhancing Glioma in Oral Presentation at the American Society of Clinical Oncology Annual Meeting

    CAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that vorasidenib and

  4. Agios to Present at the RBC Capital Markets Global Healthcare Virtual Conference on Tuesday, May 19, 2020

    CAMBRIDGE, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is

  5. Agios Reports First Quarter 2020 Financial Results and Provides Update on Business Operations and COVID-19 Response

    – First Quarter TIBSOVO® Net Revenue of $22.7 Million; Company Reiterates 2020 TIBSOVO® Net U.S. Revenue Guidance of $105–115 Million – – New Clinical Data from Mitapivat in Thalassemia Accepted for Presentation at

  6. Agios to Webcast Conference Call of First Quarter 2020 Financial Results on April 30, 2020

    CAMBRIDGE, Mass., April 16, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company

  7. Agios Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Mitapivat in Pyruvate Kinase Deficiency

    CAMBRIDGE, Mass., March 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the European

  8. Agios Provides Update on 2016 Collaboration Agreement with Celgene, a Wholly Owned Subsidiary of Bristol Myers Squibb

    – Celgene Declines to Exercise Opt-in Right for MAT2A Inhibitor AG-270 – – Research Term of the Metabolic Immuno-oncology Collaboration to Conclude at the End of the Initial Four-year Period in May 2020 – – AG-270

  9. Agios Announces FDA Clearance of Investigational New Drug Application for AG-946, a Next-Generation PKR Activator

    – Phase 1 Healthy Volunteers Study Expected to Begin in Mid-Year 2020 – CAMBRIDGE, Mass., March 23, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that the U.S. Food and Drug

  10. Agios to Present at the Cowen 40th Annual Healthcare Conference on Tuesday, March 3, 2020

    CAMBRIDGE, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is

  11. Agios Reports Fourth Quarter and Full Year 2019 Financial Results

    – Fourth Quarter TIBSOVO® Net Revenue of $19.6M and $59.9M for Full Year 2019; Full Year 2020 U.S. TIBSOVO® Net Revenue Expected to be Between $105-115 Million – – New Clinical Data from Mitapivat in Thalassemia and

  12. Agios to Present at the Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020

    CAMBRIDGE, Mass., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is

  13. Agios to Webcast Conference Call of Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020

    CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company

  14. TIO Bioventures Expands and Strengthens Team with the Appointment of Industry Veteran Rachel W. Humphrey, M.D., as Head of R&D at TIO Discovery

    Dr. Humphrey will oversee and drive clinical development efforts in TIO Bioventures' oncology-focused portfolio companies TIO Bioventures, an emerging life science venture creation fund with a mission to build

  15. TIO Bioventures Launches Treadwell Therapeutics, Seeded With $27m to Develop First-in-Class Oral Medicines Against Novel Targets

    Industry Veteran Rachel W. Humphrey, M.D., Head of R&D at TIO Discovery, appointed as Board Member and Chief Medical Officer of Treadwell Therapeutics TIO Bioventures, an emerging life science venture creation fund

  16. Agios Announces "Agios 2025" Strategic Vision and Highlights 2020 Milestones

    – In 2025, Company Expects to Have 4 Marketed Products in at Least 8 Indications, at Least 6 Molecules in Clinical Development and a Broad Research Pipeline – – Broadening Opportunities for PKR Activation: Topline Data

  17. Agios to Present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020

    CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is

  18. Agios Receives FDA Breakthrough Therapy Designation for TIBSOVO® (ivosidenib) for the Treatment of Adult Patients with Relapsed or Refractory Myelodysplastic Syndrome with an IDH1 Mutation

    CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food

  19. Agios Presents Updated Data for Mitapivat from Extension Phase of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

    – Robust Hemoglobin Increases Maintained in 18 Patients in the Extension Phase of the Study with Median Treatment Duration of Three Years – – Cumulative Safety Profile (Core Period plus Extension Phase) Continues to

  20. Agios Presents Translational Data to Further Characterize the Role of TIBSOVO® (ivosidenib) Treatment in IDH1 Mutant Acute Myeloid Leukemia (AML)

    – Combination Therapy with TIBSOVO® and Azacitidine Results in Deep and Durable Molecular Remission in Newly Diagnosed IDH1 Mutant AML – – Mechanisms of Resistance and Relapse to Single Agent IDH1 Inhibitors Are Complex

  21. Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results

    – Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients – – Safety Profile Consistent with Previously Published Phase 2 Data for Mitapivat in Patients with Pyruvate Kinase

  22. Agios Appoints Bruce Car, Ph.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of

  23. Agios Appoints Jonathan Biller as Chief Legal Officer

    CAMBRIDGE, Mass., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of

  24. Agios Presents New Pharmacodynamic and Response Data from Both Cohorts of the Perioperative Study of Vorasidenib and TIBSOVO® (ivosidenib) in Patients with IDH1 Mutant Positive Low-Grade Glioma

    – Preliminary Efficacy Data Show 31% Overall Response Rate for Both Vorasidenib and TIBSOVO® with Postoperative Treatment – – Vorasidenib and TIBSOVO® Showed 2-HG Suppression of Greater Than 90% in Resected IDH1 Mutant

  25. CStone announces first patient dosed in the Phase I bridging registrational study of ivosidenib

    SUZHOU, China, Nov. 19, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone" or the "Company", HKEX: 2616) today announced that the first patient has been dosed in the Phase I bridging registrational

  26. Agios Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares

    CAMBRIDGE, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise

  27. Agios Announces Pricing of $256 Million Public Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it has priced an underwritten public offering of 8,250,000 shares of common stock at a price to the

  28. Agios Announces Proposed Offering of Common Stock

    CAMBRIDGE, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced that it is offering to sell, subject to market and other conditions, up to 7.5 million shares of its common

  29. Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the 2019 ASH Annual Meeting

    – Important Translational Data for TIBSOVO® Underscore the High Clinical and Molecular Remissions Rate Observed in Combination with Azacitidine in IDH1 Mutant AML and Expand Understanding of Resistance Mechanisms – –

  30. Agios Reports Business Highlights and Third Quarter 2019 Financial Results

    – TIBSOVO® Net Revenue of $17.4 Million; 27% Growth from Q2 2019 – – Reported Positive Phase 3 ClarIDHy Results for TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma; sNDA Submission Planned by Year-End – –

  31. Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

    – Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg Once Daily – – Combination Arms of Phase 1 Study Evaluating AG-270 in Combination

  32. Agios to Webcast Conference Call of Third Quarter 2019 Financial Results on October 31, 2019

    CAMBRIDGE, Mass., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company

  33. Agios to Present Data from AG-270 Phase 1 Dose-Escalation Study in Patients with MTAP-Deleted Tumors in a Proffered Papers Oral Presentation and Poster Session at the AACR-NCI-EORTC International Conference

    CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the

  34. Data from Agios' Phase 3 ClarIDHy Trial of TIBSOVO® Demonstrates Significant Improvement in Progression Free Survival (PFS) Compared to Placebo in Previously Treated IDH1 Mutant Cholangiocarcinoma Patients

    – TIBSOVO® Reduced the Risk of Disease Progression or Death by 63% (HR=0.37, p<0.001); Median PFS for Patients Randomized to TIBSOVO® was 2.7 months Compared to 1.4 Months with Placebo – – TIBSOVO® Patients Had

  35. Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

    CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, announces that results from the

  36. Agios Announces Publication of Data for Mitapivat from Core and Extension Phases of the DRIVE PK Study in Patients with Pyruvate Kinase Deficiency in the New England Journal of Medicine

    –  Maximum Hemoglobin Increases >1.0 g/dL Observed in 50% of Patients in Core Period, Among Whom the Mean Maximum Hemoglobin Increase was 3.4 g/dL – – Hemoglobin Responses Maintained in 19 Patients in the Extension

  37. Agios to Present at the Citi 14th Annual Biotech Conference on Thursday, September 5, 2019

    CAMBRIDGE, Mass., Aug. 29, 2019 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is